Cardiology Business

Novartis Reclaims Anthos, Reenters Factor XI Race

Just a couple weeks after the full trial results of AZALEA TIMI 71 were released, Novartis agreed to acquire Anthos Therapeutics for $925M upfront and another $2.15B in milestone payments, signaling that the pharma titan may have renewed confidence in abelacimab and the Factor XI inhibition segment. 

  • Novartis spun out the testing and development of abelacimab and formed Anthos Therapeutics back in 2019.
  • Since then, abelacimab has shown promise for clot prevention without raising bleeding risks when compared to anticoagulants like rivaroxaban (Bayer/J&J’s Xarelto).

Abelacimab already demonstrated an edge over the incumbents, thanks to its 80% reduction in venous thromboembolism compared to enoxaparin and a 62% lower rate of major bleeding events than Xarelto in phase 2 trials. 

  • Anthos subsequently kicked off three phase 3 trials in 2022, and wrapping up these studies by 2026 will now be Novartis’ responsibility.

Besides the hefty price tag, the “re-acquisition” puts Novartis back into competition with other big-name Factor XI inhibitor developers, who’ve faced a series of setbacks.

  • Bayer terminated its OCEANIC-AF trial for its Factor XI inhibitor, asundexian, due to 3x greater stroke (1.3% vs. 0.4%) and 4x higher ischemic stroke rates (csHR = 4.06).
  • Results from BMS’ AXIOMATIC-SSP study found that its Factor XI inhibitor, milvexian, failed to meaningfully reduce ischemic stroke. 

Novartis initially prioritized its treatments for heart failure and plaque-clogged arteries when it spun-off abelacimab but continued to monitor the Factor XI race, leading to its choice to take the baton back from Anthos.

  • Novartis’ abelacimab efforts will now take a unique clinical approach since the Anthos-designed phase 3 trials focus on more than just ischemic stroke.
  • Anthos’ LILAC trial is focused on preventing stroke and systemic embolism in AFib patients, while ASTER and MAGNOLIA aim to use abelacimab to address VTE and GI cancer.

The Takeaway

Novartis’ massive investment to buy back Anthos suggests the pharma giant sees serious potential for abelacimab – despite the early troubles around other Factor XI inhibitors. We’ll have to wait and see the phase 3 results until we can say for sure.

Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Cardiology Business June 19, 2025

Lilly Buys Verve, Bringing Gene Editing Mainstream June 19, 2025

Gene editing for heart disease just got a major boost as Eli Lilly acquired Verve Therapeutics and its one-dose cholesterol drugs for up to $1.3B, marking a new path for Verve’s therapies to go mainstream. Part of the acquisition likely stems from Verve’s recent impressive trial results for its PCSK9-blocking treatment, VERVE-102, which lowered LDL-C […]

Cardiac Imaging June 19, 2025

New AI-driven Tool Aids in Mitral Valve Assessment June 19, 2025

By: Jimmy Su, Ph.D. Principal Scientist, Cardiovascular Ultrasound, Philips A new tool, Automated 3D Color Flow Quantification (3D Auto CFQ), removes the reliance on assumptions when quantifying mitral regurgitation and replaces it with a reliable and robust, AI-driven method that delivers precise measurement of mitral valve regurgitant volume (RVol) regardless of orifice shape and size. Eliminating assumptions: Quantification […]

Cardiology Pharmaceuticals June 16, 2025

No Need to Discontinue Abelacimab Pre-Procedure June 16, 2025

A new analysis of AZALEA-TIMI 71 suggests Anthos Therapeutics’ abelacimab is capable of reducing major bleeding in patients with AFib undergoing invasive procedures. The sub-analysis examined a total of 920 procedures across 441 patients taking either abelacimab or rivaroxaban, with approximately 1-in-3 patients undergoing an invasive procedure over a median follow-up of 2.1 years. Researchers […]

You might also like..

Select All

You're signed up!

It's great to have you as a reader. Check your inbox for a welcome email.

-- The Cardiac Wire Team

You're all set!